Human papillomavirus vaccine uptake among 9‐ to 17‐year‐old girls

Wong, Charlene A.; Berkowitz, Zahava; Dorell, Christina; Price, Rebecca Anhang; Lee, Jennifer; Saraiya, Mona

doi:10.1002/cncr.26246

Cited by 67 publications

(77 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Similar findings were reported by Wong (2008) in which parents with less than high school education were significantly more likely to vaccinate their daughter than parents who are high school graduates. Several studies reported that parents with lower levels of education were more likely to accept HPV vaccination for their daughters (Brewer and Fazekas, 2007;Constantine and Jerman, 2007;Rosenthal et al, 2008).…”

Section: Discussionsupporting

confidence: 85%

Practice of HPV Vaccine and Associated Factors among School Girls in Melaka, Malaysia

Al-Naggar¹,

Bobryshev²,

Al-Jashamy³

et al. 2012

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

Objective: The objective of this study is to determine the practice and associated factors of HPV vaccine among school girls in Melaka, Malaysia. Methodology: A total number of 612 secondary school girls participated in this study. The questionnaire consists of 38 questions which included 3 sections. The first section is about sociodemography. The Second section is about knowledge and awareness of HPV vaccines. The third section is about practices with associated barriers of HPV vaccination. Verbal consent was obtained from all participants, and data were analyzed using SPSS 13. Results: A total number of 612 secondary school girl students participated in this study. The mean age was 13.93±SD (1.09); minimum age was 13 years old and maximum was 17 years old. The majority of them was Malay, from rural areas and had a family monthly income of RM 3000 or less (91.8%, 53.1%, 69.6%; respectively). The majority of the parents of the school girls were with secondary education level (56.4%). The majority of the participants did not have a family history of cervical cancer (99.0%). The prevalence of HPV vaccination was 77.9% among school girls in Melaka. The majority of the participants were vaccinated in their schools (77.0%). About 69% knew about cervical cancer and 77.6% had ever heard about HPV vaccine. Regarding the factors that influence the practice of uptake HPV vaccine, they were age, race, income, parents' education, knowledge about cervical cancer, heard about HPV vaccine and place of getting the vaccine (p<0.001). Conclusion: The prevalence of HPV vaccine among school girls is high. Age, race, income, parents' education, knowledge about cervical cancer, heard about HPV vaccine and place of getting the vaccine were the significant factors that influence the practice of uptake HPV vaccine among school girls.

show abstract

Section: Discussionsupporting

confidence: 85%

Practice of HPV Vaccine and Associated Factors among School Girls in Melaka, Malaysia

Al-Naggar¹,

Bobryshev²,

Al-Jashamy³

et al. 2012

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

show abstract

“…The data also provide insight into the potential health impact of vaccination in young women in the catchup age group for vaccination, who are currently being vaccinated at higher rates than 11-to 12-year-old girls, the age group targeted for vaccination. 25,26 The prevalence of HPV in this study was extremely high, as has been shown in previous studies of young women with similar demographic characteristics. 27,28 Among participants in the prevaccination surveillance study, who were unvaccinated, 24% were already positive for at least 1 high-risk, vaccine-type HPV (HPV-16 and/or -18).…”

Section: Discussionsupporting

confidence: 79%

Vaccine-Type Human Papillomavirus and Evidence of Herd Protection After Vaccine Introduction

et al. 2012

View full text Add to dashboard Cite

WHAT'S KNOWN ON THIS SUBJECT:Clinical trials have demonstrated that prophylactic human papillomavirus (HPV) vaccines are highly effective in preventing HPV infection, but the impact of vaccination on HPV prevalence rates in real-world, community settings is uncertain. WHAT THIS STUDY ADDS:This study provides evidence of a substantial decrease in the prevalence of vaccine-type HPV among young women and evidence of herd protection in a community only 4 years after the quadrivalent HPV vaccine was licensed.abstract OBJECTIVES: The aims of this study were to compare prevalence rates of human papillomavirus (HPV) in young women before and after HPV vaccine introduction to determine the following: (1) whether vaccine-type HPV infection decreased, (2) whether there was evidence of herd protection, and (3) whether there was evidence for typereplacement (increased prevalence of nonvaccine-type HPV). METHODS:Young women 13 to 26 years of age who had had sexual contact were recruited from 2 primary care clinics in 2006-2007 for a prevaccination surveillance study (N = 368, none were vaccinated) and 2009-2010 for a postvaccination surveillance study (N = 409, 59% were vaccinated). Participants completed a questionnaire and were tested for cervicovaginal HPV DNA. HPV prevalence rates were compared in the pre-versus postsurveillance studies by using x 2 tests. Propensity score weighting was used to balance differences in covariates between the 2 surveillance studies. RESULTS:The mean age was ∼19 years for both groups of participants and most were African American and non-Hispanic. After propensity score weighting, the prevalence rate for vaccine-type HPV decreased substantially (31.7%-13.4%, P , .0001). The decrease in vaccine-type HPV not only occurred among vaccinated (31.8%-9.9%, P , .0001) but also among unvaccinated (30.2%-15.4%, P , .0001) postsurveillance study participants. Nonvaccine-type HPV increased (60.7%-75.9%, P , .0001) for vaccinated postsurveillance study participants.CONCLUSIONS: Four years after licensing of the quadrivalent HPV vaccine, there was a substantial decrease in vaccine-type HPV prevalence and evidence of herd protection in this community. The increase in nonvaccine-type HPV in vaccinated participants should be interpreted with caution but warrants further study.

show abstract

“…This is consistent with other studies that show flu vaccination is associated with HPV vaccination. 22,23 It is possible that children who receive yearly flu vaccinations have parents with more positive attitudes toward vaccination, and thus have their children HPV vaccinated as well. In addition, flu vaccination may be a marker of children and adults who have regular check-ups, and provided another point of contact with providers to distribute vaccine-related information.…”

Section: Discussionmentioning

confidence: 99%

Regional variations in HPV vaccination among 9–17 year old adolescent females from the BRFSS, 2008–2010

Hirth

Rahman

Smith

et al. 2014

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

Human papillomavirus (HPV) vaccine uptake among 18-26 y old women varies by geographic region in the US. However, little is known about regional variations in vaccination among girls who are in the vaccine's targeted age groups. Regional variation in HPV vaccination among female adolescents (9-17 y old) was examined using crosssectional data from the Behavioral Risk Factor Surveillance System (BRFSS) between 2008 and 2010. Multivariable logistic regression estimated the association of region of residence (10 states included questions about adolescent HPV vaccination) with uptake and completion of the 3-shot HPV vaccine series. Among 7,849 adolescents, 26.9% initiated, and 55.2% of initiators completed the series. Adolescents from Northeast/Midwest/West states were 1.74 (95% CI: 1.45-2.10) times more likely to have initiated HPV vaccination compared to the South/Southwestern states. Among initiators, vaccine series completion did not vary significantly between the South/Southwestern and Northeast/Midwest/West states. Flu vaccination was associated with increased odds of initiation in both regions and completion of the HPV vaccine series in the South/Southwestern states only. Girls 9-10 and 11-12 y old were less likely to have initiated and 11-12 y olds were less likely to have completed the HPV vaccine series compared to 13-17 y olds. The observed regional variations in vaccination could cause rates of cervical cancer to remain higher in the South/Southwest and widen currently observed regional disparities in cervical cancer rates.

show abstract

Human papillomavirus vaccine uptake among 9‐ to 17‐year‐old girls

Cited by 67 publications

References 41 publications

Practice of HPV Vaccine and Associated Factors among School Girls in Melaka, Malaysia

Practice of HPV Vaccine and Associated Factors among School Girls in Melaka, Malaysia

Vaccine-Type Human Papillomavirus and Evidence of Herd Protection After Vaccine Introduction

Regional variations in HPV vaccination among 9–17 year old adolescent females from the BRFSS, 2008–2010

Contact Info

Product

Resources

About